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Background: BRCA1/2 mutation carriers and women from a hereditary breast(/ovarian)
cancer family have a highly increased risk of developing breast cancer (BC). Prophylactic
mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efﬁcacy and
sequels of PM are scarce.
Methods: From 358 high-risk women (including 236 BRCA1/2 carriers) undergoing PM
between 1994 and 2004, relevant data on the occurrence of BC in relation to PM, compli-
cations in relation to breast reconstruction (BR), mutation status, age at PM and preoperative
imaging examination results were extracted from the medical records, and analyzed separately
for women without (unaffected, n = 177) and with a BC history (affected, n = 181).
Results: No primary BCs occurred after PM (median follow-up 4.5 years). In one previ-
ously unaffected woman, metastatic BC was detected almost 4 years after PM (primary BC not
found). Median age at PM was younger in unaffected women (P < .001), affected women
more frequently were 50% risk carriers (P< .001). Unexpected (pre)malignant changes at PM
were found in 3% of the patients (in 5 affected, and 5 unaffected women, respectively). In
49.6% of the women opting for BR one or more complications were registered, totaling 215
complications, leading to 153 surgical interventions (71%). Complications were mainly related
to cosmetic outcome (36%) and capsular formation (24%).
Conclusions: The risk of developing a primary BC after PM remains low after longer fol-
low-up. Preoperative imaging and careful histological examination is warranted because of
potential unexpected (pre)malignant ﬁndings. The high complication rate after breast recon-
struction mainly concerns cosmetic issues.
Key Words: BRCA1/2—Breast cancer—Mastectomy—Prevention—Complications—Unex-
pected carcinomas.
Women with a germ-line BRCA1 or BRCA2
mutation as well as 50% risk carriers from a heredi-
tary breast(/ovarian) cancer (HB(O)C) family are at
increased risk of developing breast and/or ovarian
cancer compared with the general population.1–4
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Options to reduce this risk are regular surveillance,
chemoprevention, or prophylactic surgery. Prophy-
lactic surgery includes prophylactic mastectomy (PM)
and/or prophylactic bilateral salpingo-oophorectomy
(PBSO). PM implies either a bilateral prophylactic
mastectomy (BPM) in high-risk unaffected women as
well as in high-risk women with a history of breast
cancer (BC) previously treated with breast conserving
therapy (BCT), or a contralateral prophylactic mas-
tectomy (CPM) after a unilateral therapeutic mas-
tectomy. Several studies have shown that PM
strongly reduces the risk of developing (contralateral)
breast cancer, while PBSO reduces the risk of ovarian
as well as primary breast cancer.5–10 These strategies
therefore have commonly been accepted at this mo-
ment as risk-reducing strategies for women being at
increased risk of HB(O)C.
PM, however, is a drastic and irreversible inter-
vention, and in case of breast reconstruction (BR), is
accompanied by a substantial complication rate.11
Further issues of concern with respect to PM include
changes in a womans body image and self-esteem,
changes of sexual function, and in psychological
distress.
At the Rotterdam Family Cancer Clinic, 35–51%
of women carrying a BRCA1 or BRCA2 mutation
opt for either bilateral or contralateral PM.12,13 For
women who are contemplating this intervention, it is
imperative to have reliable data on the outcomes
of PM in a well-deﬁned cohort to make a good
informed decision and to minimize postoperative
feelings of deception. At the Rotterdam Family
Cancer Clinic there is ample and long-term experi-
ence with sufﬁcient numbers of women undergoing
PM. We previously reported data concerning the
occurrence of breast cancer after BPM in unaffected
women with a proven BRCA1/2 mutation,5,14 com-
plications of PM with breast reconstruction,11,15 and
psychological aspects of PM in combination with
BR.16
In the current analysis, we report on an extended
series with longer follow-up of women having
undergone a PM at the Rotterdam Family Cancer
Clinic because of either a proven BRCA1/2 muta-
tion or a genetic susceptibility (50% risk carriers
from a HB(O)C family). Our study sample was large
enough to discriminate between unaﬀected women
and women with a history of BC (aﬀected). Special
attention is paid to the prevalence of (pre)malignant
lesions in prophylactically removed mastectomy
specimens. Further, we report on the postoperative
complications of PM in combination with breast
reconstruction.
PATIENTS AND METHODS
As of the start of the Rotterdam Family Cancer
Clinic in 1991, PM and/or PBSO are being discussed
as risk-reducing strategies with women at increased
risk of hereditary BC and/or ovarian cancer. In early
years, PM was discussed with BRCA1/2 mutation
carriers as well as with women from a HB(O)C family
without a proven mutation (so-called 50% risk car-
riers), and applied for unaﬀected as well as aﬀected
(with a history of breast cancer) women. Due to the
development of more advanced mutation-detection
methods enabling the performance of a complete
gene mutation screen, there has been a shift in more
recent years to discuss the option of PM only with
identiﬁed mutation carriers. Before 1996, the decision
to undergo a PM and/or PBSO was discussed indi-
vidually by the doctor and the woman in question. As
of 1996, women opting for either PM and/or PBSO
are additionally discussed in the multidisciplinary
Committee on Hereditary Tumors. For this purpose,
institutional guidelines concerning the surveillance
schedule and indications regarding PM/PBSO have
been further elaborated and implemented as of 2000,
which were updated as knowledge progressed and
more evidence-based data became available.
Before 2000, no additional examinations were
performed before PM, irrespective of the individual
situation (unaﬀected/aﬀected; mutation/50% risk
carrier). Women were seen biannually for physical
examination, while a mammography was performed
annually. As of 2000, institutional guidelines from the
working party on hereditary tumors recommended to
perform clinical breast examination (CBE) and
imaging examination within 3 months prior to PM, to
minimize the risk of ﬁnding unexpected malignant
changes at PM. At ﬁrst, imaging examination con-
sisted of either mammography or magnetic resonance
imaging (MRI) scan, while more recently MRI has
been preferred. Breast ultrasound (US) and, if nec-
essary, ﬁne-needle aspiration cytology (FNAC) are
additionally performed in case lesions are found at
CBE or one of the imaging examinations. Further,
the guidelines recommend the discussion of the case
in the multidisciplinary Committee on Hereditary
Tumors and a standard visit with a psychologist. For
aﬀected women, the guidelines are extended with
dissemination investigations to rule out recurrent or
distant breast cancer activity (chest x-ray, liver
ultrasound, bone scan, liver functions and determi-
nation of Ca15.3/Ca125). Where women with a his-
tory of ovarian cancer were previously eligible for
PM, at the moment this is not discussed anymore in
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this setting, because the prognosis is mainly dictated
by the ovarian cancer. In the sample, these women
were classiﬁed as ‘‘unaﬀected,’’ unless they also had a
history of BC.
To evaluate the short-term and long-term medical
eﬀects of prophylactic surgery in high-risk women, a
combined retrospective and prospective, longitudinal
study was activated at our institution, including all
genetically susceptible women who had opted for
prophylactic surgery (either PM and/or PBSO).
Women were informed by oral and written informa-
tion and were asked for written consent. The protocol
was approved by the institutional review board
(project EMC-DDHK 98-15).
Surgical Technique
At our institute, the oncological and plastic sur-
geon perform the PM and BR as a team. During the
operation, the patient is under general anesthesia in a
half-supine position. A skin-sparing mastectomy is
performed through a vertical, peri-areolar incision,
which extends from just above the nipple down the
submammary fold. The breast tissue, including the
superﬁcial fascia (creating thin skin ﬂaps), the axillary
tail, the inframammary fold, the nipple-areolar
complex, and the fascia of the pectoral muscle are
removed. In case of immediate breast reconstruction,
either a subpectoral silicone implant is inserted in a
pocket created below the pectoral muscles in a one-
stage procedure, or autologeous tissue is used. Au-
tologeous reconstruction encompasses a broad range
of procedures incorporating the patients own tissues
to recreate the breast. The transverse rectus abdomis
myocutaneous (TRAM) ﬂap and latissimus dorsi ﬂap
are two standard myocutaneous ﬂaps used for breast
reconstruction. More recent modiﬁcations to the
traditional techniques led to the use of the deep
inferior epigastric perforator (DIEP) ﬂap. Nipple
reconstruction is oﬀered after 6 months and consists
of three small transposition ﬂaps; the areola is mim-
icked by tattooing the desired skin color. Breast
reconstruction is not always performed in the same
operation as the mastectomy; the techniques for these
delayed reconstructions, however, are as described
previously.
Microscopic Examination of Mastectomy Specimens
As of 1995, a standard procedure has been fol-
lowed for meticulous microscopic examination of
prophylactically removed mastectomy specimens to
rule out the presence of ‘‘occult’’ (microscopic)
malignant alterations. The protocol prescribes that
mastectomy specimens are cut into slices of 0.5–1 cm
thickness, whereby each slice is carefully inspected
and palpated for abnormalities. Standard, three
randomly selected parenchymal tissue samples from
each quadrant and a transverse section through the
nipple are submitted for histology, in addition to
samples of all visible or palpable abnormalities.
Further, three samples from each quadrant of the
mastectomy specimens are snap frozen for the tissue
bank. Radiographic examination of breast tissue
specimens is not performed on a routine basis.
Study Design
The current study included all women at increased
risk of hereditary BC, according to previously de-
scribed criteria,17 who underwent prophylactic bilat-
eral or contralateral mastectomy between January 1,
1994 until December 31, 2004. Of our study cohort
310 women (86.6%) underwent PM at our clinic,
while 48 women (13.4%) were treated elsewhere, e.g.,
due to a waiting list at our clinic, or the fact that
previous surgery was performed elsewhere. The latter
women were only eligible for this analysis if the fol-
low-up after PM took place at our clinic, and a copy
of the pathology report was available. In general,
DNA testing was performed before the prophylactic
surgery, although some women choose for prophy-
lactic surgery without or irrespective of DNA testing.
DNA analysis was performed according to standard
procedures, as has been previously described.18,19
DNA testing was not an inclusion criterion for par-
ticipation in the study. Proven noncarriers from a
family BRCA mutation were excluded from the
study.
Relevant data were extracted from the hospital
records. For each woman, including deceased wo-
men, the following information was obtained: date of
birth, death, and PM, performance (yes/no) and type
of breast reconstruction, PBSO, diagnosis of breast
and/or ovarian cancer, mutation status, duration of
follow-up after PM (end date being either the date of
death or the date of last clinic visit in case of loss to
follow-up, or the end date of this study, i.e. December
31, 2004), and type and number of complications
after breast reconstruction. Regarding the latter, we
distinguished between early (within 6 weeks) and late
postoperative complications (after 6 weeks). Early
complications consisted of infection, necrosis, bleed-
ing, and luxation of the prosthesis. Late complica-
tions were divided in surgical complications (such as
capsular formation, infection, necrosis, and luxation
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of the prosthesis), and complaints related to cosmetic
outcome (such as poor symmetry and dog ears).
Nipple reconstruction is regarded as part of the
breast reconstruction and therefore has not been
registered as a cosmetic complication. A computer-
ized database (MS-Access) was used to process the
data. Data were entered retrospectively as well as
prospectively after each clinic visit.
Statistical Analysis
Descriptive statistics (median, range, and fre-
quency) were computed. When appropriate, statisti-
cal signiﬁcance testing between relevant subgroups
was performed using the chi-square test for categor-
ical variables and a t-test for continuous variables. A
P value of less then .05 was considered statistically
signiﬁcant.
RESULTS
Study Population
In Table 1 the characteristics of the women who
underwent a PM are shown. A total of 358 women,
with a median follow-up after PM of 4.5 years, ful-
ﬁlled the study eligibility criteria, consisting of 181
(50.6%) women with a history of breast cancer (af-
fected women), and 177 (49.4%) women without a
history of BC (unaffected women). A total of 236
(65.9%) women were BRCA1/2 mutation carriers,
while the other 122 women (34.1%) were 50% risk
carriers from a HB(O)C family. The unaffected group
mainly consisted of BRCA1/2 mutation carriers as
compared with 50% risk carriers (82% vs 18%, P <
.001), whereas the affected group consisted of an
equal number of mutation carriers and 50% risk
TABLE 1. Characteristics of the study population
HISTORY OF BC No (Unaffected, n = 177) Yes (Affected, n = 181)
P valued
BRCA HB(O)C BRCA HB(O)C
n (%)a n (%)a n (%)a n (%)a
No. of women (N) 145 (82)b 32 (18)b 91 (50)c 90 (50)c <.001e
Death due to cancer 0 (0) 1 (3) 9 (10) 7 (8)
Age at PM (years)
Median 36.0 38.5 42.0 47.0 <.001
Range 22–65 28–55 25–65 26–68
<30 years 18 (12) 3 (9) 6 (7) 2 (2) <.001
30–39 years 74 (51) 14 (44) 26 (29) 22 (24)
40–49 years 36 (25) 10 (31) 38 (42) 31 (34)
‡50 years 17 (12) 5 (16) 21 (23) 35 (39)
Duration of follow-up (years) 4.4 4.7 3.9 4.5
Mutation status
BRCA1 115 (79) – 76 (84) –
BRCA2 30 (21) – 15 (16) –
PBSO
Yes 83 (57) 3 (9) 61 (67) 12 (13) .13
No 62 (43) 29 (91) 30 (33) 78 (87)
Age at PBSO (years)
Median 40.0 45.0 43.0 49.0 <.01
Range 29–57 35–45 32–65 37–58
Timing of PBSO
Before PM 18 (22) 2 (67) 14 (23) 6 (50) .11
At PM 35 (42) 1 (33) 16 (26) 5 (42)
After PM 30 (36) 0 (0) 31 (51) 1 (8)
Ovarian cancer before PM 4 (3) 0 (0) 2 (2) 1 (1)
Unexpected (p)MF at PM 3 (2) 2 (6) 4 (4) 1 (1)
Cancer after PM
Breast cancer 1 (1) 0 (0) 0 (0) 0 (0)
Ovarian cancer 2 (1) 0 (0) 1 (1) 0 (0)
BC, breast cancer; HB(O)C, hereditary breast(/ovarian) cancer; PM, prophylactic mastectomy; PBSO, prophylactic bilateral salpingo-
oophorectomy; (p)MF, (pre)malignant ﬁndings.
a Percentage of the number of women in column in question, unless stated otherwise.
b Percentage of unaffected women.
c Percentage of affected women.
d Difference between unaffected and affected BRCA1/2 mutation carriers, unless stated otherwise.
e Difference in distribution between unaffected and affected women.
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carriers (91 mutation carriers versus 90 50% risk
carriers, P = .94). This difference in distribution was
highly signiﬁcant (P < .001).
The median age at PM in the unaﬀected and af-
fected group was signiﬁcantly diﬀerent, being 37 and
44 years, respectively (Table 2, P < .001). In the af-
fected group, mutation carriers were signiﬁcantly
younger at PM than 50% risk women (42 vs 47 years,
respectively; P = .045). In the unaffected group, we
found no signiﬁcant difference in this respect (36 vs
38.5 years, respectively; P = .102). A history of
ovarian cancer was present in four mutation carriers
from the unaffected group (2.3%), and in three wo-
men (1.7%) in the affected group.
In Fig. 1, the number of PMs per year, separately
for unaffected/affected BRCA mutation carriers, as
well as for unaffected/affected 50% risk carriers is
shown. In the unaffected group, the annual number
of women undergoing PM was always larger in
mutation carriers compared with 50% risk carriers,
except for the ﬁrst 2 years (1994/1995). Further, the
number of unaffected BRCA mutation carriers
undergoing PM widely differed over the years, with
two peaks in 1998 and 2001, respectively. In contrast,
the number of unaffected 50% risk carriers under-
going PM was quite stable over the years.
In the aﬀected group, however, the pattern was
diﬀerent, whereby a shift has taken place through the
years. In the early years of the study period (1994–
1997), mainly women without a proven mutation
underwent PM in this group. Between 1997 and 2001,
approximately as many mutation carriers as 50% risk
carriers underwent a PM. As of 2002, more mutation
carriers have undergone a PM, although the number
of PMs in 2004 again was not different between
mutation and 50% risk carriers.
Prophylactic Bilateral Salpingo-oophorectomy
A considerable part of the BRCA mutation carriers
undergoing PM also opted for PBSO, being 57% in
the unaﬀected versus 67% in the aﬀected group,
respectively (Table 1, P = .13). In the HB(O)C
group, however, only a minority of the women
underwent a PBSO, being 15 of 122 50% risk carriers
(12%). The median age at PBSO was younger in
BRCA mutation carriers compared with the 50% risk
carriers, both in the affected and the unaffected
group. This difference, however, was not signiﬁcant
(P = .13 and P = .40, respectively). Further, the
median age at PBSO was lower in the unaffected
compared with the affected group, being 40 versus 44
years, respectively (Table 2, P < .001). In addition,
unaffected BRCA mutation carriers underwent
PBSO at a younger age compared with mutation
carriers with a history of BC (40 vs 43 years,
respectively, P < .01, Table 1).
(Pre)malignant Findings at PM
In 10 of the 358 women (2.8%), abnormal ﬁndings
were unexpectedly found in the mastectomy speci-
mens (table 1). Prior to intended PM there was no
suspicion to justify an axillary nodal dissection in
combination with the PM procedure. This occurred
in ﬁve ‘‘unaffected’’ (2.8 %) as well as in ﬁve previ-
ously affected women (2.8%), and in both mutation
carriers (3%) and 50% risk carriers (2.5%).
TABLE 2. Comparison between unaffected and affected
women
Unaffected Affected P value
No. of women (N) 177 (%) 181 (%)
Age at PM (years)
Median 37 44 <.001
Range 22–65 25–68
<30 years 21 (12) 8 (4) <.001
30–39 years 88 (50) 48 (27)
40–49 years 46 (26) 69 (38)
‡50 years 22 (12) 56 (31)
PBSO
Yes 86 (49) 73 (40) .12
No 91 (51) 108 (60)
Age at PBSO (years)
Median 40 44 <.001
Range 29–57 32–65
PM, prophylactic mastectomy; PBSO, prophylactic bilateral
salpingo-oophorectomy.
FIG. 1. Annual number of PM in unaffected/affected BRCAa/2
mutation carriers and 0% risk carriers from HB(O)C families.
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The characteristics of the unexpected (pre)malig-
nant ﬁndings as well as the preoperative screening
results are chronologically described in detail in Ta-
ble 3. In 1995, in one woman both preoperative
clinical breast examination (CBE) and mammogra-
phy were suspicious for a malignancy. However,
additional investigation, consisting of ultrasound and
cytology, did not reveal a malignancy. Nevertheless,
histological examination of the mastectomy speci-
mens revealed an invasive ductal carcinoma (IDC),
eventually staged as a pTxN1Mo. The patient died of
metastatic breast cancer 4 years after the PM. In
another two women, undergoing PM in 1996 and
1997, a lesion was found preoperatively (CBE and
mammography, respectively) and classiﬁed as prob-
ably benign. No malignant abnormalities were seen at
subsequent ultrasound examination, which is the
reason a FNAC was not performed. However, his-
tological examination of the mastectomy specimens
revealed a small ductal carcinoma in situ (DCIS) in
both women. In 2002, in one woman preoperative
MRI revealed a lesion classiﬁed as probably benign.
Indeed, no malignant abnormalities were found at
additional ultrasound examination. Histological
examination of the mastectomy specimens, however,
revealed an IDC in the right, and an invasive me-
dullar carcinoma (IMC) in the left breast. Preopera-
tive screening in the remaining six women, performed
1–6 months preceding PM, did not show suspicious
abnormalities. Still, another invasive carcinoma,
three cases of DCIS, and two cases of lobular carci-
noma in situ (LCIS) were found in the mastectomy
specimens. All unexpected (pre)malignant findings in
the affected women were found in the contralateral
breast.
Cancer During Follow-up After PM
After PM, no incident breast cancer cases were
observed in 50% risk carriers.
In BRCA mutation carriers, ovarian cancer was
detected in two women in the unaﬀected group, and
in one woman in the aﬀected group (Table 1).
One BRCA1 mutation carrier from the unaﬀected
group presented in 2001, 3.5 years after PM (no
malignant ﬁndings at histological examination), with
metastatic adenocarcinoma in an axillary lymph
node, morphologically and immunohistochemically
consistent with breast cancer. Additional dissemina-
tion examinations also revealed metastases in bone
and liver. Review of the preoperative data (physical
examination and mammography) at the presentation
of metastatic disease did not show malignant altera-
tions, while meticulous reexamination of all pathol-
ogy slides and additional investigation of frozen
tissue material did not detect a primary breast cancer.
Reconstructive Breast Surgery
In Table 4, the numbers and types of recon-
structive breast surgery, as well as the numbers and
types of complications after breast reconstruction
(BR) are shown. Of the total population (n = 358),
276 women underwent BR in combination with PM,
TABLE 3. Characteristics of unexpected (pre)malignant ﬁndings in the PM specimens
Preoperative
Year of PM
Genetic risk
group
History of BC
before PM Histology Grade Tumor size (mm) ER/PR status CBE Mx MRI
1995 HB(O)C No IDC NA NA NA SC SC a, b
1996 HB(O)C No DCIS II <2 NA PB nl a
1996 BRCA1 No LCIS NA NA NA nl nl
1997 HB(O)C Yes DCIS I NA NA nl c
1997 BRCA1 Yes DCIS II <2 NA nl PB a
1997 BRCA1 Yes IDC II 3 Negative nl c
1998 BRCA1 Yes DCIS NA <2 NA nl nl
2000 BRCA1 Yes LCIS NA NA NA nl nl
2002 BRCA1 No IDC III 5 Negative nl nl PB a
IMC III 6 Positive
2003 BRCA2 No DCIS II <2 NA nl nl
PM, prophylactic mastectomy; BC, breast cancer; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; IDC, invasive ductal
carcinoma; IMC, invasive medullar carcinoma; CBE, clinical breast examination; Mx, mammography; MRI, magnetic resonance imaging;
SC, suspicion of cancer; PB, probably benign; nl, normal; NA, not applicable.
a Additional investigation normal.
b Macroscopic palpable tumor; microscopic no clear border, therefore tumor size and grade not determinable.
c Treated previously for BC at another hospital. No information about preoperative imaging available.
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being 60% unaffected and 40% affected women. The
presence or absence of a BRCA1/2 mutation did not
inﬂuence the BR rate (P = .23 for unaffected, and P
= .10 for affected women), or the type of BR (P =
.25 for unaffected, and P = .68 for affected wo-
men). Unaffected women mainly opted for BR
(94%), consisting of 163 immediate and three de-
layed reconstructions, while a considerable part
of the affected women did not opt for BR (37%)
(P < .001). Further, unaffected women mainly
opted for BR by means of (silicon) prosthesis (96%).
In contrast, affected women opting for BR (102
immediate, and 8 delayed) more often had a
reconstruction by means of autologeous tissue
compared with unaffected women, being 13% versus
3%, respectively (P = .004).
In 137 of 276 women opting for BR (49.6%) one or
more complications were registered, totaling 215
TABLE 4. Breast reconstruction (BR) in women undergoing PM
History of BC
No (Unaffected) Yes (Affected)
P valueNumber of women 177 (%) 181 (%)
Breast reconstruction (BR)
No 9 (5) 68 (37) <.001
Yes 166 (94) 110 (61)
Unknown a 2 (1) 3 (2)
Type of BR
Silicon prosthesis 159 (96) 95 (86) .004
Autologeous tissue 6 (3) 14 (13)
Unknown a 1 (1) 1 (1)
Therapy ﬁrst BC b
BCT – – 7 (6)
BCT/RT – – 33 (30)
MAST – – 67 (67)
MAST/RT – – 3 (3)
Women with complications after BR
No 84 (51) 55 (50) .92
Yes 82 (49) 55 (50)
Total number of complications after BR c 127 88
Early (<6 weeks after BR) 42 (33) 31 (35) .74
Late (>6 weeks after BR) 85 (67) 57 (65)
Surgery due to late complication
No 38 (30) 24 (27) .67
Yes 89 (70) 64 (73)
Early complications
Surgery due to early complication
No 27 (64) 17 (55) .42
Yes 15 (36) 14 (45)
Type of early complication
Infection 8 (19) 14 (45) .09
Necrosis 11 (26) 4 (13)
Bleeding 20 (48) 12 (39)
Prosthesis luxation 2 (5) 0 (0)
Poor arterial inﬂow 0 (0) 1 (3)
Pneumothorax 1 (2) 0 (0)
Late complications
Surgery due to late complication
No 11 (13) 7 (12) .91
Yes 74 (87) 50 (88)
Type of late complication
Infection 4 (4) 0 (0) .33
Necrosis 1 (1) 3 (5)
Capsular formation 31 (37) 20 (35)
Prosthesis luxation 2 (2) 3 (5)
Poor cosmetic appearance d 31 (37) 19 (34)
Dog ear 16 (19) 12 (21)
PM, prophylactic mastectomy; BC, breast cancer; BR, breast reconstruction; BCT, breast conserving therapy; BCT/RT, BCT in combi-
nation with radiotherapy; MAST, therapeutic mastectomy; MAST/RT, MAST in combination with radiotherapy.
a Surgery performed at another hospital, not included in P value calculation.
b Data shown for women with a BR after PM.
c One woman can have ‡1 complication.
d Including asymmetry.
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complications. Surgical reinterventions were per-
formed in 153 cases (124 for late complications).
Concerning the number of complications, this was
not diﬀerent between unaﬀected and aﬀected women,
neither for the moment of the complication (i.e., early
or late) (P = .74), the necessity of reintervention due
to the complication (P = .67), nor for the type
of complication (P= .09 for early complications and
P = .33 for late complications).
DISCUSSION
In this study we updated and extended the long-
term experiences at the Rotterdam Family Cancer
Clinic with prophylactic mastectomy (PM) in proven
BRCA1/2 mutation carriers and in 50% risk carriers
from a HB(O)C family. We compared the data of PM
and breast reconstruction (if performed) in women
with (aﬀected) and without a personal history of BC
(unaﬀected women) and further distinguished be-
tween women with a BRCA 1 or 2 mutation, and
women without a proven mutation. While within the
unaﬀected group, especially BRCA1/2 mutation
carriers opted for PM, we observed that within the
aﬀected group an equal number of mutation carriers
and 50% risk carriers from a HB(O)C family opted
for PM. Women carrying a BRCA 1 or 2 mutation
are known to have an increased risk of developing
contralateral primary BC,20,21 which is even more
apparent among women who are younger when
diagnosed with a primary breast carcinoma (age <50
years).22,23 For high-risk women without a proven
mutation inconsistent results on the risk of develop-
ing a contralateral breast cancer (CBC) were re-
ported. Shahedi et al.24 as well as Kirova et al.25
reported an increased risk of developing CBC in non-
BRCA1/2 women, while Tilanus et al.26 concluded
that the rate of CBC was only slightly and insigniﬁ-
cantly increased in non-BRCA1/2 compared with
sporadic breast cancer patients. In view of these re-
sults, one expects that after a ﬁrst diagnosis of breast
cancer, especially mutation carriers will opt for pro-
phylactic removal of the remaining breast tissue. In
our study sample, however, also a considerable part
of the women without a proven BRCA1/2 mutation
opts for prophylactic mastectomy, especially after a
history of breast cancer. It has to be mentioned that,
since information on the BRCA1/2 mutation status is
not always known in the latter group and genetic
testing is missing a number of mutations, it is likely
that some of these patients are in fact mutation car-
riers. Further, the group of women with a history of
breast cancer, with and without a gene mutation, may
partly consist of women who initially chose for sur-
veillance, and eventually opted for PM after the
diagnosis of breast cancer. This is in accordance with
an earlier report indicating that women may be more
likely to undergo PM after a previous diagnosis of
BC.27 This might also partly explain the higher age at
the time of PM in the group with a history of BC.
We found that the age at PM was younger in
unaﬀected women, both for mutation carriers as for
50% risk carriers. Further, we found a signiﬁcant
diﬀerence between unaﬀected and aﬀected mutation
carriers in the distribution of the numbers of PM over
the various age categories, with the highest numbers
of PM in the age group of 30–40 for unaffected and
40–50 for affected carriers, respectively. Moreover,
the distribution of PM over the various age categories
remained completely identical to the age distribution
reported in a previous study on PM from our insti-
tute,5 indicating consistency over time.
Our data show that, despite preoperative (imaging)
examination, the presence of unexpected microscopic
(pre)malignant ﬁndings in this group of high-risk
women is real (3%). Other studies reporting on high-
risk and/or pathologic ﬁndings in prophylactically
removed breast tissues, described percentages varying
from 0.1–57%.8,27–29 However, the comparison of
frequencies of unexpected (pre)malignant ﬁndings
between studies is hampered by differences in popu-
lation selection, preoperative screening methods,
pathological examination of the specimens, and def-
inition of what is considered (pre)malignant [e.g.,
lobular carcinoma in situ (LCIS)]. The percentage of
unexpected invasive carcinomas in these studies ran-
ged from 0.1–7.7% (0.8% in our study). Most of these
studies, however, did not provide information about
the outcome of preoperative physical breast or
imaging examination, which at the moment is a
standard procedure at our institution. It might be
that since the implementation of institutional guide-
lines concerning preoperative breast examination in
2000, and the introduction of magnetic resonance
imaging (MRI), being more sensitive in detecting
carcinomas in high-risk women,30,31 as detection tool,
the number of unexpected malignant ﬁndings in the
PM specimens is decreasing.
With a 3% incidence of unexpected microscopic
(pre)malignant ﬁndings, the potential role of sentinel
node biopsy (SN) for all patients undergoing PM has
been discussed. However, the majority of the
(pre)malignant ﬁndings we found in this series, rep-
resents DCIS/LCIS; settings for which a sentinel
node biopsy is not standardly indicated. Invasive
B. A. M. HEEMSKERK-GERRITSEN ET AL.3342
Ann. Surg. Oncol. Vol. 14, No. 12, 2007
cancer was found in only 0.8% of the patients in this
series. Therefore, in our opinion, routine use of SN in
all patients undergoing PM is not warranted, which is
also supported in the paper by Boughey et al.32
A previous study from our institution, investigat-
ing the eﬃcacy of PM in unaﬀected women with a
proven BRCA1/2 mutation, observed no cases of
breast cancer after PM.5 The mean follow-up in that
study was 3 years. In the current cohort, one BRCA1
mutation carrier presented with metastatic disease 3.5
years after PM (no primary BC found), suggesting
the presence of an occult primary tumor that was
never found, despite a thorough reexamination of the
specimen at the presentation of the metastatic dis-
ease. This ﬁnding emphasizes the fact that despite
thorough examination of the mastectomy specimens,
the presence of an occult breast cancer cannot be
ruled out completely and indicates that a form of
surveillance after PM might be relevant.
The number of reconstructions after risk-reducing
mastectomy was lower in the aﬀected group. This
may be due to the fact that BR after previous
radiotherapy and/or therapeutic mastectomy not al-
ways leads to satisfactory cosmetic results.15,33 Some
patients abandon, in consultation with and/or at the
advice of their (oncological/plastic) surgeon, from
BR for this reason. Other women have accepted the
mutilation/alteration of body image caused by mas-
tectomy, are reluctant to undergo renewed surgery,
and prefer the use of external prosthesis.
During the follow-up period of this study, 49.6% of
the women with immediate or delayed BR after PM
showed complications. In total 215 complications
were registered, leading to surgical reintervention in
153 cases. These ﬁndings are consistent with several
other reports,34,35 though there are also studies
reporting lower,11,15,33 or even higher36 complication
rates after (immediate) BR. However, the literature in
this area is difﬁcult to compare, in part because not all
previous series compare bilateral prophylactic mas-
tectomy in unaffected women with risk-reducing
mastectomies in women after a previous therapy for
breast cancer. Furthermore, data may not be compa-
rable because of different deﬁnitions of complications.
Moreover, some studies describe the complication rate
as a percentage of the total number of reconstruc-
tions,11,15,33 while others, like our study, present the
percentage of women with complications.34–36
We found no diﬀerences in the numbers of com-
plications after (immediate) breast reconstruction in
unaﬀected women compared with previously aﬀected
women in this study. This ﬁnding appears to be
in contrast with earlier reports (also from our
institution) describing the occurrence of more com-
plications after mastectomy followed by (immediate)
breast reconstruction in aﬀected women. These
studies report negative eﬀects of preoperative radio-
therapy on the cosmetic outcome of the reconstruc-
tion, in particular the risk of capsular formation
would be increased, having negative consequences on
the symmetry of the breasts. Further, asymmetry can
be expected to occur more often after previous ther-
apeutic mastectomy. Although we have no explana-
tion for our ﬁndings, it is possible that the experience
of the surgeons at our institution is important. In-
deed, where previously BR by means of silicon
prosthesis after breast conserving therapy was per-
formed, this is not done anymore.
In summary, we conﬁrmed our previous ﬁndings
that prophylactic mastectomy strongly reduces the
risk of developing breast cancer in both BRCA1/2
mutation carriers and 50% risk carriers. As the fre-
quency of unexpected cancers in this high-risk group
remains real, preoperative imaging and careful his-
tological examination is warranted. Further, we
found a substantial complication rate after breast
reconstruction, which mainly concerned late cosmetic
issues, almost always leading to additional surgery. In
this respect, patients should be informed preopera-
tively that an optimal cosmetic eﬀect cannot uncon-
ditionally be achieved in just one single operation.
Concerning the complication rate after BR, we did
not ﬁnd a signiﬁcant diﬀerence between aﬀected and
unaﬀected women. In our opinion, our data are
providing additional data on this issue and may help
to inform women considering prophylactic mastec-
tomy and their physicians, in the complex process of
decision-making.
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